BMN

BlackRock Announces Release of Commentaries for Certain Closed-End Funds (BIGZ, BSTZ, BMEZ, BCAT, ECAT, and BMN) and Private Investment Report

Retrieved on: 
Thursday, August 24, 2023
Consulting, Banking, Professional Services, Finance, Risk, BMN, Research, Trust law, Investment, Trustee, Security (finance), Trust

The Trust seeks to return $25.00 per common share (the initial public offering price per common share) to holders of common shares on or about September 30, 2037.

Key Points: 
  • The Trust seeks to return $25.00 per common share (the initial public offering price per common share) to holders of common shares on or about September 30, 2037.
  • For more information on BlackRock’s closed-end funds, please visit www.blackrock.com/CEF
    Carefully consider each Trust’s investment objective, risk factors, and charges and expenses before investing.
  • This and other information can be found in each Trust’s shareholder report which may be obtained by visiting the SEC Edgar database.
  • Privately issued debt securities are often of below investment grade quality, frequently are unrated and present many of the same risks as investing in below investment grade public debt securities.

Blockstream Bets on ASIC Market Recovery with Launch of New 'BASIC Note' Investment Vehicle

Retrieved on: 
Wednesday, August 16, 2023
Application-specific integrated circuit, Note, Miner, BMN, Capital, BTC, BASIC, Cryptocurrency, Bitcoin, EU, Blockstream, ASIC

MONTREAL, Aug. 16, 2023 /PRNewswire-PRWeb/ -- Leading Bitcoin infrastructure company Blockstream has partnered with Luxembourg-based STOKR, the EU's pioneering digital investment marketplace for alternative assets, to introduce a unique investment vehicle: The Blockstream ASIC (BASIC) Note.

Key Points: 
  • MONTREAL, Aug. 16, 2023 /PRNewswire-PRWeb/ -- Leading Bitcoin infrastructure company Blockstream has partnered with Luxembourg-based STOKR, the EU's pioneering digital investment marketplace for alternative assets, to introduce a unique investment vehicle: The Blockstream ASIC (BASIC) Note.
  • "The BASIC Note arrives at an opportune time in the market, presenting a unique and carefully timed investment opportunity for any bitcoin-focused portfolio."
  • Prices for Bitcoin miners, or ASICs, rose materially during the last bitcoin bull market, before crashing as the subsequent bear market deepened, reaching a bottom in December 2022.
  • "The BASIC Note arrives at an opportune time in the market, presenting a unique and carefully timed investment opportunity for any bitcoin-focused portfolio."

BlackRock Announces Release of Fourth Quarter Commentaries for Certain Closed-End Funds (BIGZ, BSTZ, BMEZ, BCAT, ECAT, and BMN)

Retrieved on: 
Thursday, February 16, 2023
Finance, Consulting, Banking, Accounting, Professional Services, BMN, Prospectus, Risk, Trustee, Security (finance), Trust

The Trust seeks to return $25.00 per common share (the initial public offering price per common share) to holders of common shares on or about September 30, 2037.

Key Points: 
  • The Trust seeks to return $25.00 per common share (the initial public offering price per common share) to holders of common shares on or about September 30, 2037.
  • For more information on BlackRock’s closed-end funds, please visit www.blackrock.com/CEF
    Carefully consider each Trust’s investment objective, risk factors, and charges and expenses before investing.
  • This and other information can be found in each Trust’s prospectus which may be obtained by visiting the SEC Edgar database.
  • Read the prospectus carefully before investing.

BlackRock 2037 Municipal Target Term Trust Announces Initial Distribution

Retrieved on: 
Tuesday, January 3, 2023
Asset Management, Professional Services, Finance, NYSE, BMN, BlackRock, CUSIP, Trustee, Cryptocurrency

The Board of Trustees of BlackRock 2037 Municipal Target Term Trust (NYSE: BMN, CUSIP: 09262G108) (the “Trust”) announced today the Trust’s initial monthly distribution, payable on February 1, 2023. Details are as follows:

Key Points: 

The Board of Trustees of BlackRock 2037 Municipal Target Term Trust (NYSE: BMN, CUSIP: 09262G108) (the “Trust”) announced today the Trust’s initial monthly distribution, payable on February 1, 2023. Details are as follows:

OTC Markets Group Welcomes Bannerman Energy Ltd to OTCQX

Retrieved on: 
Wednesday, September 7, 2022
Terbium, CEO, PFS, OTC, Uranium, OTCQX, SIPC, Alternative trading system, DFS, SEC, Erongo Region, ATS, GLOBE, Company, Compliance, BMN, Dysprosium, ASX, Awka South, FINRA, Rare-earth element, Financial adviser, Security (finance)

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Bannerman Energy Ltd (ASX: BMN; OTCQX: BNNLF), a company which engages in exploration and development of uranium properties in Namibia, Southern Africa, has qualified to trade on the OTCQX Best Market.

Key Points: 
  • NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Bannerman Energy Ltd (ASX: BMN; OTCQX: BNNLF), a company which engages in exploration and development of uranium properties in Namibia, Southern Africa, has qualified to trade on the OTCQX Best Market.
  • Bannerman Energy Ltd upgraded to OTCQX from the OTCQB Venture Market.
  • About OTC Markets Group Inc.
    OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities.
  • OTC Link ATS, OTC Link ECN and OTC Link NQB are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

Retrieved on: 
Thursday, July 7, 2022
Patient, Carmine, Achondroplasia, CEO, Medarex, B cell, Novartis, Pulmonology, Physiology, BMS, Amoxicillin/clavulanic acid, Bay, BioMarin Pharmaceutical, Nobel Prize, Senior advisor, Formoterol, SA, BMN, Nobel Prize in Physiology or Medicine, CMO, MBA, Non-executive director, GlaxoSmithKline, SVP, Bristol Myers Squibb, Haemophilia, EVP, Physician, Royal Australasian College, Royal college, Sangamo Therapeutics, VP, Board, Multiple myeloma, Drug development, Batten disease, Lymphatic system, Pharmaceutical industry, Pegvaliase, Medicine, Omalizumab, Phenylketonuria

Bryce Carmine, HaemaLogiX's Chairman and CEO commented: "Geoff's impressive, globally recognised background in drug development, and in particular, in antibody development, makes him a valuable contribution to the HaemaLogiX board.

Key Points: 
  • Bryce Carmine, HaemaLogiX's Chairman and CEO commented: "Geoff's impressive, globally recognised background in drug development, and in particular, in antibody development, makes him a valuable contribution to the HaemaLogiX board.
  • Importantly, during his time at Medarex, Geoff oversaw the preclinical and clinical development of KappaMab, our multiple myeloma drug candidate.
  • He brings outstanding industry knowledge and a highly translatable skillset to our Board mix.
  • Dr. Nichol brings nearly 30 years' experience in drug development.

Lifshitz Law Firm, P.C. Announces Investigations of BioMarin Pharmaceutical Inc. (NASDAQGS: BMRN), On24, Inc. (NYSE: ONTF), Silverback Therapeutics, Inc. (NASDAQ: SBTX), and Selectquote, Inc. (NYSE: SLQT)

Retrieved on: 
Wednesday, April 13, 2022
Gorilla, Telephone, IPO, Atlanta Silverbacks U23's, COVID-19, BMN, Defendant, Hewlett, Prospectus, Contract, Company, Advertising, BioMarin Pharmaceutical, FDA, Class, Pharmaceutical industry, Online shopping

If you are a BioMarin investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are a BioMarin investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • If you are a ONTF investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • 2022 Lifshitz Law PLLC The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.
  • Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Ardelyx, BioMarin, Chegg, and ChemoCentryx on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 5, 2022
BMRN, Phase, Lists of schools in England, Student, BioMarin Pharmaceutical, Safety, ANCA, FDA, Growth, NYSE, BMN, Company, II, COVID-19, Anti-neutrophil cytoplasmic antibody, Squire, Complaint, GLOBE, NASDAQ, Animal, Audit, Generic drug, Pharmaceutical industry, Chegg, P.C

Bragar Eagel & Squire is investigating certain officers and directors of Ardelyx, Inc. following a class action complaint that was filed against Ardelyx on July 30, 2021.

Key Points: 
  • Bragar Eagel & Squire is investigating certain officers and directors of Ardelyx, Inc. following a class action complaint that was filed against Ardelyx on July 30, 2021.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • To learn more about our investigation into Chegg go to: https://bespc.com/cases/CHGG
    Bragar Eagel & Squire is investigating certain officers and directors of ChemoCentryx, Inc. following a class action complaint that was filed against ChemoCentryx on May 5, 2021.
  • To learn more about our investigation into ChemoCentryx go to: https://bespc.com/cases/CCXI
    About Bragar Eagel & Squire, P.C.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.

Retrieved on: 
Thursday, February 3, 2022
BMN, Fraud, FDA, BioMarin Pharmaceutical, NASDAQ, Pharmaceutical industry

is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) on behalf of stockholders.

Key Points: 
  • is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) on behalf of stockholders.
  • On October 25, 2021, a class action complaint was filed against BioMarin.
  • The complaint alleges that, between January 13, 2020 and September 3, 2021, defendants made materially false and misleading statements regarding BioMarin's business, operations, and compliance policies.
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] .

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.

Retrieved on: 
Monday, January 24, 2022
Nasdaq, BioMarin Pharmaceutical, FDA, BMRN, Fraud, BMN, GLOBE, Pharmaceutical industry

is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. (BioMarin) (NasdaqGS: BMRN ) on behalf of long-term stockholders.

Key Points: 
  • is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. (BioMarin) (NasdaqGS: BMRN ) on behalf of long-term stockholders.
  • On October 25, 2021, a class action complaint was filed against BioMarin.
  • The complaint alleges that, between January 13, 2020 and September 3, 2021, defendants made materially false and misleading statements regarding BioMarins business, operations, and compliance policies.
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].